ER+ breast cancers typically showed relatively mild clinical outcomes compared to estrogen-negative (ER-) breast cancers, including HER2-positive and triple-negative breast cancer (Mesa-Eguiagaray et al. 2020). The gene discussed is ERBB2; the disease is breast carcinoma.